Valvular Abnormalities Detected by Echocardiography in 5-Year Survivors of Childhood Cancer: A Long-Term Follow-Up Study
Creators
- 1. Department of Pediatric Oncology, Emma Children's Hospital/Academic Medical Center, Amsterdam (Netherlands)
- 2. Department of Medical Oncology, Emma Children's Hospital/Academic Medical Center, Amsterdam (Netherlands)
- 3. Department of Radiation Oncology, Emma Children's Hospital/Academic Medical Center, Amsterdam (Netherlands)
- 4. Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Emma Children's Hospital/Academic Medical Center, Amsterdam (Netherlands)
- 5. Department of Cardiology, Emma Children's Hospital/Academic Medical Center, Amsterdam (Netherlands)
- 6. Department of Epidemiology, Netherlands Cancer Institute, Amsterdam (Netherlands)
Description
Purpose: To determine the prevalence of valvular abnormalities after radiation therapy involving the heart region and/or treatment with anthracyclines and to identify associated risk factors in a large cohort of 5-year childhood cancer survivors (CCS). Methods and Materials: The study cohort consisted of all 626 eligible 5-year CCS diagnosed with childhood cancer in the Emma Children's Hospital/Academic Medical Center between 1966 and 1996 and treated with radiation therapy involving the heart region and/or anthracyclines. We determined the presence of valvular abnormalities according to echocardiograms. Physical radiation dose was converted into the equivalent dose in 2-Gy fractions (EQD2). Using multivariable logistic regression analyses, we examined the associations between cancer treatment and valvular abnormalities. Results: We identified 225 mainly mild echocardiographic valvular abnormalities in 169 of 545 CCS (31%) with a cardiac assessment (median follow-up time, 14.9 years [range, 5.1-36.8 years]; median attained age 22.0 years [range, 7.0-49.7 years]). Twenty-four CCS (4.4%) had 31 moderate or higher-graded abnormalities. Most common abnormalities were tricuspid valve disorders (n=119; 21.8%) and mitral valve disorders (n=73; 13.4%). The risk of valvular abnormalities was associated with increasing radiation dose (using EQD2) involving the heart region (odds ratio 1.33 per 10 Gy) and the presence of congenital heart disease (odds ratio 3.43). We found no statistically significant evidence that anthracyclines increase the risk. Conclusions: Almost one-third of CCS treated with potentially cardiotoxic therapy had 1 or more asymptomatic, mostly mild valvular abnormalities after a median follow-up of nearly 15 years. The most important risk factors are higher EQD2 to the heart region and congenital heart disease. Studies with longer follow-up are necessary to investigate the clinical course of asymptomatic valvular abnormalities in CCS
Availability note (English)
Available from http://dx.doi.org/10.1016/j.ijrobp.2014.09.010Additional details
Identifiers
- DOI
- 10.1016/j.ijrobp.2014.09.010;
- PII
- S0360-3016(14)04096-6;
Publishing Information
- Journal Title
- International Journal of Radiation Oncology, Biology and Physics
- Journal Volume
- 91
- Journal Issue
- 1
- Journal Page Range
- p. 213-222
- ISSN
- 0360-3016
- CODEN
- IOBPD3
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 46129784
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- CARDIOVASCULAR DISEASES; CHILDREN; CONGENITAL DISEASES; DIAGNOSIS; DOSE EQUIVALENTS; HAZARDS; HEART; HOSPITALS; NEOPLASMS; RADIATION DOSES; RADIOTHERAPY; REGRESSION ANALYSIS; VALVES
- Descriptors DEC
- AGE GROUPS; ANIMALS; BODY; BUILDINGS; CARDIOVASCULAR SYSTEM; CONTROL EQUIPMENT; DISEASES; DOSES; EQUIPMENT; FLOW REGULATORS; MAMMALS; MAN; MATHEMATICS; MEDICAL ESTABLISHMENTS; MEDICINE; NUCLEAR MEDICINE; ORGANS; PRIMATES; RADIOLOGY; STATISTICS; THERAPY; VERTEBRATES
Optional Information
- Copyright
- Copyright (c) 2015 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.